Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.60 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010377 | 1.00 | MME (0.60) | MMEENPEPNPY1RNPY2RNPY4R | |
| SCHEMBL30010408 | 1.00 | MME (0.60) | MMEENPEPNPY1RNPY2RNPY4R | |
| SCHEMBL30010358 | 1.00 | MME (0.60) | MMEENPEPNPY1RNPY2RNPY4R | |
| SCHEMBL30010232 | 0.96 | MME (0.66) | MMEENPEPACE | |
| SCHEMBL30011801 | 0.96 | MME (0.66) | MMEENPEPACE | |
| SCHEMBL30011159 | 0.96 | MME (0.66) | MMEENPEPACE | |
| SCHEMBL30011828 | 0.96 | MME (0.66) | MMEENPEPACE | |
| SCHEMBL30011726 | 0.96 | MME (0.66) | MMEENPEPACE | |
| SCHEMBL31025645 | 0.96 | MME (0.64) | MMEENPEPNPY1RNPY2RNPY4R | |
| SCHEMBL31025643 | 0.96 | MME (0.64) | MMEENPEPNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083844-A1 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | H LEE MOFFITT CANCER CT & RES (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250333542-A1 | INTERFERON GAMMA VARIANTS AND ANTIGEN BINDING MOLECULES COMPRISING THESE | HOFFMANN-LA ROCHE INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12415843-B2 | Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-16 | — | — | US | disclosed |
| US-12410226-B2 | Interferon-gamma biased agonists | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-09 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| EP-4499229-A1 | INTERFERON GAMMA VARIANTS AND ANTIGEN BINDING MOLECULES COMPRISING THESE | F. Hoffmann-La Roche AG (CH) | 2025-02-05 | — | — | EP | disclosed |
| CN-119095880-A | Interferon gamma variants and antigen binding molecules comprising these variants | 豪夫迈·罗氏有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| WO-2023186756-A1 | INTERFERON GAMMA VARIANTS AND ANTIGEN BINDING MOLECULES COMPRISING THESE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-10-05 | — | — | WO | disclosed |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11672877-B2 | In vivo immunoimaging of interferon-gamma | WAYNE STATE UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
| CN-109475640-B | Mixed carrier for nucleic acid carried article | 库瑞瓦格欧洲公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | CUREVAC AG (DE) | 2022-10-25 | — | — | US | disclosed |
| CN-107266579-B | Fusion proteins for the treatment of metabolic diseases | 诺华股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220177598-A1 | TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | HNRNPH1, HNRNPH3, SNRPE | MME 1902/4885ENPEP 1575/4885NPY1R 3867/4885 |
| US-20260083844-A1 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | NOS2, NOS1, NOS3 | MME 2521/4885ENPEP 1217/4885NPY1R 4265/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | MME 2664/4885ENPEP 910/4885NPY1R 2188/4885 |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | MME 1902/4885ENPEP 1575/4885NPY1R 3867/4885 |
| US-11672877-B2 | In vivo immunoimaging of interferon-gamma | IFNG, IFNAR1, FCGR2A | MME 1100/4885ENPEP 92/4885NPY1R 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.